NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRI)

Compare
1.2300 +0.2961 (+31.71%)
At close: October 31 at 4:00 PM EDT
1.2400 +0.01 (+0.81%)
After hours: October 31 at 7:59 PM EDT
Loading Chart for BFRI
DELL
  • Previous Close 0.9339
  • Open 0.8364
  • Bid 0.8700 x 500
  • Ask 1.5300 x 2800
  • Day's Range 0.7946 - 2.2101
  • 52 Week Range 0.6100 - 4.7700
  • Volume 132,368,479
  • Avg. Volume 2,482,210
  • Market Cap (intraday) 6.819M
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7400
  • Earnings Date Nov 9, 2024 - Nov 24, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.50

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

www.biofrontera-us.com

83

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BFRI

View More

Performance Overview: BFRI

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BFRI
55.60%
S&P 500
19.62%

1-Year Return

BFRI
67.63%
S&P 500
36.93%

3-Year Return

BFRI
98.50%
S&P 500
23.89%

5-Year Return

BFRI
98.50%
S&P 500
23.89%

Compare To: BFRI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BFRI

View More

Valuation Measures

Annual
As of 10/31/2024
  • Market Cap

    6.76M

  • Enterprise Value

    3.82M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.11

  • Price/Book (mrq)

    0.62

  • Enterprise Value/Revenue

    0.11

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.34%

  • Return on Assets (ttm)

    -40.24%

  • Return on Equity (ttm)

    -149.41%

  • Revenue (ttm)

    35.24M

  • Net Income Avi to Common (ttm)

    -13.51M

  • Diluted EPS (ttm)

    -2.7400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.39M

  • Total Debt/Equity (mrq)

    13.20%

  • Levered Free Cash Flow (ttm)

    -17.96M

Research Analysis: BFRI

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 7.84M
Earnings -257k
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.00
11.50 Average
1.2300 Current
16.00 High
 

Company Insights: BFRI

People Also Watch